2.55  -1.16 (-31.27%)		04-24 16:00
Open: 3.65 High: 3.7 Volume: 62,678		Pre. Close: 3.71 Low: 2.2 Market Cap: 46(M)

Short term
Mid term
Targets	6-month :	4.01	1-year :	4.9
Resists	First :	3.43	Second :	4.19
Pivot price	3.42
Supports	First :	2.2	Second :	1.83
MAs	MA(5) :	3.58	MA(20) :	3.43
	MA(100) :	4.19	MA(250) :	5.05
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	62.1	D(3) :	82.9
RSI	RSI(14): 32
52-week	High :	6.8	Low :	2.2

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GNTA ] has closed below the lower bollinger band by 13.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ GNTA ] is to continue within current trading range. It is unclear right now based on current values. 64.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	3.7 - 3.73	3.73 - 3.74
Low:	2.17 - 2.18	2.18 - 2.2
Close:	2.52 - 2.55	2.55 - 2.57

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Tue, 17 Jan 2023
Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer - Business Wire

Tue, 04 Oct 2022
ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New ... - GlobeNewswire

Mon, 22 Nov 2021
Genenta Science: Advancing Cancer Immunogene Therapies - Seeking Alpha

Thu, 25 Apr 2024

Thu, 25 Apr 2024

Thu, 25 Apr 2024

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	18 (M)
Shares Float	11 (M)
Held by Insiders	38.8 (%)
Held by Institutions	6.6 (%)
Shares Short	3 (K)
Shares Short P.Month	4 (K)

EPS	-0.69
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.12
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-26.3 %
Return on Equity (ttm)	-45.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.65
Qtrly Earnings Growth	0 %
Operating Cash Flow	-11 (M)
Levered Free Cash Flow	-8 (M)

PE Ratio	-3.75
PEG Ratio	0
Price to Book value	2.27
Price to Sales	0
Price to Cash Flow	-4.15

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.